Depression
-
Upload
aadharhospital -
Category
Healthcare
-
view
132 -
download
0
Transcript of Depression
DEPRESSION
Dr. Prasanna Prabhakar Khatawkar
M.B.B.S., D.P.M., F.A.G.E., D.N.B. (Psychiatry)
Consultant Psychiatrist
www.mhgi.in
A. FIVE OR MORE SYMPTOMS STATED BELOW:* PRESENT FOR TWO OR MORE WEEKS* SUGGEST A DEFINITE CHANGE FROM EARLIER
BEHAVIOUR* INCLUDES AT LEAST ONE OF THE
FOLLOWING: ~ DEPRESSED MOOD ~ DECREASED INTEREST OR PLEASURE.
* SYMPTOMS INCLUDE: 1. SUBJECTIVE REPORT OF DEPRESSED MOOD
DIAGNOSTIC CRITERIA: DSM-IV
www.mhgi.in
2. DECREASED INTEREST
3. SIGNIFICANT WEIGHT-LOSS OR WEIGHT-GAIN
4. INSOMNIA OR HYPERSOMNIA
5. PSYCHOMOTOR AGITATION OR RETARDATION.
6. FATIGUE OR LOSS OF ENERGY
7. FEELINGS OF WORTHLESSNESS AND EXCESSIVE OR INAPPROPRIATE GUILT
8. RECURRENT THOUGHTS OF DEATH.
www.mhgi.in
B. SIGNIFICANT SOCIO-OCCUPATIONAL DYSFUNCTION.
C. SYMPTOMS NOT SUGGESTIVE OF SUBSTANCE OR GENERAL MEDICAL CONDITION.
D. NOT OCCURRING DURING BEREAVEMENT
www.mhgi.in
OTHER IMPORTANT FEATURES:
1. IMPROVEMENT IN SYMPTOMS TOWARDS EVENING
2. MULTIPLE SOMATIC COMPLAINTS
3. HEIGHTENED PERCEPTION TO PAIN
4. ALEXITHYMIA
5. TEARFULNESS
6. ANXIETY SYMPTOMS
7. PSEUDODEMENTIA
8. MOOD CONGRUENT PSYCHOTIC FEATURES
www.mhgi.in
COGNITIVE TRIAD of
DEPRESSION
• NEGATIVE EVALUATION OF SELF• NEGATIVE EVALUATION OF THE WORLD• PESSIMISTIC EXPECTATIONS OF FUTURE
www.mhgi.in
PATHOGENETIC AETIOLOGIC
MODEL OF DEPRESSION
•LIMBIC-DIENCEPHALIC DYSFUNCTION
•NA SYSTEM DYSFUNCTION LEADING TO ALTERED LIMBIC AND CORTICAL AROUSAL
EARLY LOSS HEREDITY GENDER
AFFECTIVE TEMPERAMENTS STRESSORS
www.mhgi.in
• 5-HT SYSTEM DYSFUNCTION• DOPAMINERGIC SYSTEM
DYSFUNCTION
• ALTERED RECEPTOR SENSITIVITY
• DYSFUNCTION OF HPA AND HPT AXES
www.mhgi.in
•ALTERATION OF SLEEP NEUROPHYSIOLOGY
•CEREBRAL METABOLIC ALTERATIONS
•IMMUNOLOGIC DEPRESSION
www.mhgi.in
ATYPICAL DEPRESSION
• REVERSAL OF VEGETATIVE SYMPTOMS, i.e.,
1. SLEEP
2. APPETITE
3. SEXUAL FUNCTION
• LEADEN PARALYSIS• REJECTION SENSITIVITY
www.mhgi.in
ANTIDEPRESSANTS
1. SSRIs (SELECTIVE 5-HT REUPTAKE INHIBITORS)
2. SDRIs (SELECTIVE DOPAMINE REUPTAKE INHIBITORS)
3. SNRIs (SELECTIVE 5-HT NE REUPTAKE INHIBITORS)
4. SARIs (SEROTONIN ANTAGONISTS/REUPTAKE INHIBITORS)
www.mhgi.in
5. NaSSAs (NA-SPECIFIC 5-HT ANTIDEPRESSANTS)
6. NRIs (NE REUPTAKE INHIBITORS)
7. TCAs (TRICYCLIC ANTIDEPRESSANTS)
8. RIMAs (REVERSIBLE INHIBITORS OF
MAO-A)9. MAOIs (MONOAMINE OXIDASE
INHIBITORS)
10. OTHER DRUGS: THYROID SUPPLEMENTS
STIMULANT DRUGS
LITHIUM
www.mhgi.in
SELECTIVE 5-HT REUPTAKE
INHIBITORS (SSRIs): ADVANTAGES
• SAFETY• TOLERABILITY• NOT LETHAL IN OVERDOSAGE• NO CARDIOTOXICITY• NO ANTICHOLINERGIC SIDE EFFECTS• WIDER THERAPEUTIC SPECTRUM.• USUAL MAINTENANCE DOSE IS THE
STARTING DOSE
www.mhgi.in
SELECTIVE 5-HT REUPTAKE
INHIBITORS (SSRIs):SHORTCOMINGS
• NOT AS EFFECTIVE AS TCAs/SNRIs IN CASES OF SEVERE DEPRESSION
• SIDE EFFECTS ARE BOTHERSOME IF NOT LETHAL
• SEXUAL DYSFUNCTION• AGITATION
www.mhgi.in